| Trial ID: | L2166 |
| Source ID: | NCT02567994
|
| Associated Drug: |
Teneligliptin
|
| Title: |
Tenelia Triple Combination Study
|
| Acronym: |
TETRIS
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Teneligliptin
|
| Outcome Measures: |
Primary: Change of HbAlc from baseline at Week 24, 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Handok Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
201
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-04
|
| Completion Date: |
2017-12
|
| Results First Posted: |
|
| Last Update Posted: |
2018-05-02
|
| Locations: |
Samsung Medical Center, Seoul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02567994
|
